Kura Oncology (NASDAQ:KURA) Downgraded by Zacks Investment Research

Zacks Investment Research cut shares of Kura Oncology (NASDAQ:KURA) from a hold rating to a sell rating in a research note issued to investors on Tuesday, Zacks.com reports.

According to Zacks, “Kura Oncology, Inc. is a biopharmaceutical company. The company is involved in the discovery and development of therapeutics for the treatment of tumors and blood cancers. Its product pipeline includes small molecule drug candidates which are in different clinical trial consists of Tipifarnib-HRAS, Tipifarnib-PTCL, ERK inhibitor program and Menin MLL inhibitor program. Kura Oncology, Inc. is headquartered in La Jolla, California. “

A number of other brokerages have also issued reports on KURA. BMO Capital Markets raised their price target on shares of Kura Oncology from $70.00 to $80.00 in a report on Friday, January 7th. JMP Securities reissued a buy rating and issued a $26.00 price target on shares of Kura Oncology in a report on Wednesday, December 15th. Credit Suisse Group cut their price target on shares of Kura Oncology from $40.00 to $21.00 and set an outperform rating on the stock in a report on Friday, November 26th. HC Wainwright cut their price target on shares of Kura Oncology from $43.00 to $32.00 and set a buy rating on the stock in a report on Wednesday, November 24th. Finally, Wedbush reaffirmed an outperform rating on shares of Kura Oncology in a research report on Monday, November 8th. One research analyst has rated the stock with a sell rating and five have assigned a buy rating to the stock. According to data from MarketBeat, Kura Oncology presently has a consensus rating of Buy and an average price target of $39.67.

KURA stock opened at $13.64 on Tuesday. Kura Oncology has a 52 week low of $12.02 and a 52 week high of $36.27. The firm’s fifty day moving average is $14.69 and its 200 day moving average is $17.29. The firm has a market cap of $907.82 million, a P/E ratio of -7.10 and a beta of 1.55.

Kura Oncology (NASDAQ:KURA) last released its earnings results on Thursday, November 4th. The company reported ($0.50) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.54) by $0.04. During the same quarter in the prior year, the business posted ($0.42) EPS. As a group, equities analysts predict that Kura Oncology will post -2.01 earnings per share for the current fiscal year.

Several large investors have recently bought and sold shares of KURA. FORA Capital LLC purchased a new position in Kura Oncology during the 2nd quarter valued at about $27,000. Royal Bank of Canada grew its holdings in Kura Oncology by 56.4% in the third quarter. Royal Bank of Canada now owns 6,894 shares of the company’s stock worth $129,000 after purchasing an additional 2,487 shares during the period. Virtus ETF Advisers LLC grew its holdings in Kura Oncology by 31.7% in the second quarter. Virtus ETF Advisers LLC now owns 9,572 shares of the company’s stock worth $200,000 after purchasing an additional 2,304 shares during the period. Jump Financial LLC purchased a new stake in Kura Oncology in the second quarter worth about $223,000. Finally, Ergoteles LLC grew its holdings in Kura Oncology by 20.3% in the second quarter. Ergoteles LLC now owns 17,800 shares of the company’s stock worth $371,000 after purchasing an additional 3,000 shares during the period.

About Kura Oncology

Kura Oncology, Inc operates as a clinical-stage biopharmaceutical company which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia; KO-947 which is an ERK inhibitor for MAPK Pathway Tumors; and KO-539 which is a Menin MLL inhibitor for acute leukemias.

Recommended Story: What are the benefits of a portfolio tracker?

Get a free copy of the Zacks research report on Kura Oncology (KURA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Kura Oncology (NASDAQ:KURA)

Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.